In a 40-week type 2 diabetes trial, weekly semaglutide lowered blood sugar and body weight more than the tested doses of weekly dulaglutide. That’s useful if you’re comparing Ozempic injection with Trulicity for diabetes. If the priority is lowering heart or kidney risks, their U.S. indications give you a different comparison. Neither injection is approved for weight management.
What did Trulicity and Ozempic do in the same diabetes trial?
SUSTAIN 7 randomized 1,201 adults whose type 2 diabetes was inadequately controlled on metformin alone. The participants stayed on metformin and received a weekly injection over 40 weeks. This was an open-label study, so people knew which drug they were taking. SUSTAIN 7 original trial
| Weekly injections compared | Average HbA1c reduction at 40 weeks | Average weight loss at 40 weeks |
|---|---|---|
| Semaglutide 0.5 mg vs. dulaglutide 0.75 mg | 1.5 vs. 1.1 percentage points | 4.6 vs. 2.3 kg |
| Semaglutide 1 mg vs. dulaglutide 1.5 mg | 1.8 vs. 1.4 percentage points | 6.5 vs. 3.0 kg |
HbA1c reflects average blood sugar over the preceding few months. A fall from 8.2% to 6.7%, for example, is a reduction of 1.5 percentage points. Weight change is given in kilograms. The two columns can inform different conversations about the same regimen.
Does this prove which drug is better for weight loss?
It shows a greater average weight reduction for semaglutide at the tested doses in adults with type 2 diabetes taking metformin. The study didn’t compare Ozempic 2 mg with Trulicity 3 mg or 4.5 mg, test Ozempic tablets, or enroll people for obesity treatment without diabetes. If weight management is your goal, ask about products with that indication. Wegovy shares Ozempic’s active ingredient and has its own approved uses and doses. Ozempic injection label · Trulicity label · Ozempic versus Wegovy
What if reducing heart or kidney risks is part of your care?
Use the eligibility criteria for the outcome you want to discuss. The 40-week HbA1c and weight results didn’t establish which injection better protects the heart or kidneys.
| U.S. approved use | Trulicity injection | Ozempic injection |
|---|---|---|
| Improve blood sugar with diet and exercise | Adults and children aged 10 and older with type 2 diabetes | Adults with type 2 diabetes |
| Reduce risk of major cardiovascular events | Adults with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors | Adults with type 2 diabetes and established cardiovascular disease |
| Reduce specific kidney outcomes and cardiovascular death in adults with type 2 diabetes and chronic kidney disease | No corresponding indication | Approved to reduce sustained decline in kidney filtration, end-stage kidney disease and cardiovascular death |
Major cardiovascular events include cardiovascular death, nonfatal heart attack and nonfatal stroke. If you have several risk factors and no diagnosed cardiovascular disease, ask the clinician whether you meet Trulicity’s cardiovascular criteria and what else should be part of your prevention plan. If you have type 2 diabetes and chronic kidney disease, ask which kidney outcome the proposed treatment is intended to affect. The answer may matter more to you than a few kilograms in a shorter trial. Trulicity prescribing information, sections 1 and 14.5 · Ozempic prescribing information, sections 1 and 14
What should you check before your next prescription?
Bring your most recent HbA1c if you have it, your current medicines and a reason you’re comparing these two. If you’re taking insulin or a sulfonylurea, ask what glucose monitoring you’ll need and whether the prescriber plans a change. Both labels warn that taking one of these GLP-1 medicines with insulin or a sulfonylurea can increase the risk of low blood sugar. Trulicity label, section 5 · Ozempic injection label, section 5
Both injections are weekly. The U.S. labels list a single-dose pen for Trulicity and single-patient pens for Ozempic injection that contain more than one dose. If handling the device or paying for the next refill is the sticking point, ask the pharmacist to show you the actual device, and check whether your plan covers that product. If agreeing to a change, leave with a written plan for the next dose and the date of the next glucose review. Trulicity label, section 16 · Ozempic injection label, sections 16 and 17

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.



